UBS Group »

Liminatus Pharma shares owned by UBS Group

Quarter-by-quarter ownership of Liminatus Pharma (LIMNW) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Liminatus Pharma

Tip: Access up to 7 years of quarterly data

All positions including Liminatus Pharma held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Liminatus Pharma by UBS Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $43 290 0.15
2025-06-30 $485 2.0k 0.24

More positions owned by UBS Group

Spdr S&p 500 Etf Tr Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Amazon (AMZN)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl A (GOOGL)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl C (GOOG)
Ubs Group SHS (UBS)
Tesla Motors (TSLA)
Ishares Tr Russell 2000 Etf (IWM)
Visa Com Cl A (V)

View all positions for UBS Group

Top funds holding Liminatus Pharma

Clear Street
Aristeia Capital
Linden Advisors
Saba Capital Management
Highbridge Capital Management
Moore Capital Management
Polar Securities
MMCAP International Inc. SPC
Nomura Holdings
Falcon Edge Capital
D. E. Shaw & Co
Millennium Management
Wolverine Asset Management
Blue Owl Capital Holdings
Periscope Capital

View all funds holding Liminatus Pharma